Jasper Therapeutics stock holds Market Outperform rating at JMP despite setback

Published 10/07/2025, 10:12
Jasper Therapeutics stock holds Market Outperform rating at JMP despite setback

Investing.com - Citizens JMP has reiterated its Market Outperform rating and $12.00 price target on Jasper Therapeutics (NASDAQ:JSPR) despite a recent setback in the company’s CSU clinical trial program. The stock, currently trading at $3.68, has experienced significant volatility, falling over 45% in the past week. According to InvestingPro data, analyst targets range from $4 to $65, reflecting diverse views on the company’s potential.

The research firm attributed the disappointing update to a "bad drug lot" but maintained its positive outlook based on briquilimab’s differentiated schedule and risk/reward profile compared to competitors. JMP highlighted the drug’s 73% complete response rate and 82% well-controlled disease at 12 weeks, which it views favorably against Celldex (NASDAQ:CLDX)’s barzolvolimab. InvestingPro analysis shows the company maintains a strong liquidity position with cash exceeding debt, though it’s currently burning through cash reserves rapidly.

JMP expressed confidence in Jasper’s opportunity to salvage its BEACON trial by restarting existing patients on the drug and enrolling new patients. The firm estimates 10-12 new patients will need to be enrolled before September to have complete 12-week data by the end of the fourth quarter of 2025.

According to JMP, Jasper management indicated that protocol amendments should take approximately two weeks, with rapid enrollment possible since clinical sites are already operational. The firm considers enrolling at least eight patients "certainly plausible" given the timeline.

JMP believes the combined data from approximately 10-11 restarted patients plus roughly eight new patients across two dosing cohorts should provide sufficient information to evaluate the compound’s feasibility by December. With a market capitalization of just $55.28 million, InvestingPro analysis indicates the stock is currently undervalued relative to its Fair Value. Subscribers can access 12 additional ProTips and a comprehensive research report for deeper insights into JSPR’s financial health and market position.

In other recent news, Jasper Therapeutics announced a significant corporate reorganization, reducing its workforce by 50% to concentrate efforts on briquilimab development for chronic urticaria. The company has halted all other clinical and preclinical programs to focus on this priority, aiming to extend its cash runway. In the wake of these developments, several analysts have adjusted their outlook on Jasper Therapeutics. Citizens JMP lowered its price target from $70 to $12, citing a disappointing readout due to manufacturing issues, but maintained a Market Outperform rating, noting briquilimab’s potential differentiation. BMO Capital downgraded the stock from Outperform to Market Perform, mentioning challenges in interpreting trial data due to potential manufacturing complications. Evercore ISI also reduced its price target from $50 to $20, maintaining an Outperform rating, and expects Jasper to resolve current issues and enroll additional patients. Cantor Fitzgerald downgraded the stock from Overweight to Neutral, expressing concerns over clinical trial setbacks and development timelines. These recent developments highlight the challenges and strategic shifts Jasper Therapeutics is navigating in its focus on chronic urticaria treatments.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.